Liver International

Article	Citations
Issue Information	245
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	107
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	101
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	98
HBV cure—The light at the end of the tunnel?	87
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	87
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	84
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	77
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	72
Inside Front Cover	71
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	67
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	64
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	62
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	60
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	60
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	59
Issue Cover	59
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?	58
Think twice about IgG4‐related diseases before operating on hepatic masses	58
High prevalence of porto‐sinusoidal vascular disease in patients with constantly elevated gamma‐glutamyl transferase levels	56
Bringing evidence to the MAFLD‐MASLD debate	52
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	51
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	50
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	50
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	49

Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	49
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders	46
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	46
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population	44
Hospitalisations With Cryoglobulin‐Related Diseases in Spain Over 25 Years	43
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	42
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability	42
Autoimmune hepatitis triggered by COVID‐19: A report of two cases	41
Integrating PNPLA3 into clinical risk prediction	40
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Findings	39
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design	39
RETRACTION: Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Internal Ribosome Entry Site‐Mediated Translation	39
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis	39
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	38
Reply: Herbal‐Induced Liver Injury Identification and Prevention	38
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	36
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	35
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	35
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’	35
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	35
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions	34
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	34
Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto‐Sinusoidal Vascular Disorder	34
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	34
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa	33
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy	33
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	33
Prognosis of hospitalized patients with cirrhosis and acute kidney disease	32
Assessment of PBC Pruritus From the ITCH‐E Study: Quality of Life, Productivity, and Treatment Experiences	32
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS‐VB Trial	32
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	32
Response to: Impact of GLP‐1RA on Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	31
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use	31
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?	31
166Ho‐RadioEmbolizaTiOn Using personalized prediCtive dosimetry in patients with Hepatocellular carcinoma: A prospective, single‐centre study (RETOUCH)	31
Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022	31
	31
Unravelling the Complex Role of Glycine‐Conjugated Bile Acids and Gut‐Liver Axis in Progressive Alcohol‐Related Liver Disease	31
Multiple arterial‐phase MRI with gadoxetic acid improves diagnosis of hepatocellular carcinoma ≤3.0 cm	31
Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF‐κB Pathway	30
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis	30
HLA matching between donors and recipients improves clinical liver transplant graft survival	30
Enhancing the Understanding of Obesity and Liver Health: Addressing Lifestyle, Socio‐economic and Ethnic Disparities	30
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024	30
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study	29
Role of Gut‐Derived Endotoxins in Porto‐Sinusoidal Vascular Disorder: Comparison Between patients with and without portal hypertension	29
Health‐related quality of life in patients with primary sclerosing cholangitis: A longitudinal population‐based cohort study	29
Red meat intake, faecal microbiome, serum trimethylamine N‐oxide and hepatic steatosis among Chinese adults	29
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis	29
Issue Information	29

Hepatic cell junctions: Pulling a double‐duty	28
Myeloid Glutamine Synthetase Protects Against Acute Liver Injury in Mice Independent of Its Enzyme Activity	27
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures	27
Case‐based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management	27
HERACLIS_BLV_D: Increasing Response Rates During 2‐Year Bulevirtide Real‐Life Therapy in Chronic Hepatitis D	27
Letter to the editor regarding “Exploring the landscape of steatotic liver disease in the general US population”	26
Gender differences of authors of major Hepatology society guidelines during the past 15 years	26
Bulevirtide for patients with compensated chronic hepatitis delta: A review	26
Patients hospitalized with alcohol‐related liver disease and prior bariatric surgery are more prone to develop acute‐on‐chronic liver failure	26
Autoimmune hepatitis (AIH) following coronavirus (COVID‐19) vaccine—No longer exclusive to mRNA vaccine?	26
Axon guidance molecules in liver pathology: Journeys on a damaged passport	26
Brain metabolic and microstructural alterations associated with hepatitis C virus infection, autoimmune hepatitis and primary biliary cholangitis	25
Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients	25
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice	25
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis	25
Response to letter from Skouloudi et al	25
Outcomes and management in paediatric autoimmune hepatitis presenting as acute liver failure: Individual patient data meta‐analysis	25
An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution	25
Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome	25
Appraisal of AI‐Based Fibrosis Quantification in MASH	24
Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets	24
NSBBs, EBL or Combined Therapy for High‐Risk Varices: Systematic Review and Meta‐Analysis	24
Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes	23
Hepatitis C screening during SARS‐CoV‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno	23
Author's reply: Plasma corticosteroid‐binding globulin levels in cirrhosis	23
Enhanced muscle function in cause‐specific mortality among patients with NAFLD‐related sarcopenia	23
Third dose of mRNA COVID‐19 vaccine and response: Correspondence	23
Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta‐analysis	22
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	22
3‐Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor?	22
Predictors of mid‐term survival after liver transplantation in patients with NAFLD cirrhosis	21
Extrahepatic autoimmune diseases do not increase the mortality of autoimmune hepatitis	21
Is it time to get rid of the biopsy mandate in adults with suspected autoimmune hepatitis? Lessons from the COVID‐19 pandemic	21
The changing epidemiology of liver diseases in Asia	21
Issue Information	21
Apolipoprotein A‐1 protected hepatic ischaemia–reperfusion injury through suppressing macrophage pyroptosis via TLR4–NF‐κB pathway	21
Issue Information	21
Trends in prevalence of probable fibrotic non‐alcoholic steatohepatitis in the United States, 1999–2016	21
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study	21
On‐treatment gamma‐glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients	21
Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure	21
Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?	21
Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation	21
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey	21
Issue Information	21
Practice patterns and outcomes associated with intravenous albumin in patients with cirrhosis and acute kidney injury	20
Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory	20
Treatment and the prognosis of hepatocellular carcinoma in Asia	20
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021	20
Practical recommendations for biochemical and genetic diagnosis of the porphyrias	20
Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways	20
Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma	20
Response to Letter to the Editor: ‘Nanoplastics and MASLD: Unveiling Interorgan Crosstalk and Environmental Modulators’	20
Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage peroxisome proliferator‐activated receptor gamma to prevent non‐alcoholic steatohepatitis progression in mice	19
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series	19
Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)	19
Global trends and the impact of chronic hepatitis B and C on disability‐adjusted life years	19
Response to Letter to the Editor: “Advancing TMPRSS6‐Targeted Therapy for MASLD: Mechanistic and Translational Perspectives”	19
Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort	19
An ultrasound multiparametric method to quantify liver fat using magnetic resonance as standard reference	19
Digital Histopathology and AI: A New Era of Liver Fibrosis Quantification	19
NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database	19
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	18
Alcohol‐related liver disease phenotype impacts survival after an acute variceal bleeding episode	18
Issue Information	18
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetes	18
Reply to the letter “Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B”	18
Issue Information	18
The utility of hierarchical genetic testing in paediatric liver disease	18
Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg‐positive donors to HBsAg‐negative recipients	18
Issue Information	18
Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial	18
Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis	17
Follow‐up post‐HCV virological response to DAA in advanced chronic liver disease	17
MASLD and MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint	17
Refining the Safety Perspective of Bulevirtide in Chronic Hepatitis Delta Management	17
Altered ethanol metabolism and increased oxidative stress enhance alcohol‐associated liver injury in farnesoid X receptor‐deficient mice	17
Future anti‐HDV treatment strategies, including those aimed at HBV functional cure	17
Pilot hepatitis C micro‐elimination strategy in Pakistani migrants in Catalonia through a community intervention	17
Management, outcomes and survival of an Australian IgG4‐SC cohort: The MOSAIC study	17

Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent	17
French guidelines on TIPS: Indications and modalities	17
Risk factors for bleeding hepatocellular adenoma in a United States cohort	17
Response Letter to: Expanding Perspectives on FIB‐4 as a Predictor of Hepatic and Extrahepatic Malignancy Risk	17
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	17
Ketogenic Diet and Hepatic Ischaemia–Reperfusion Injury: Aggravation or Mitigation?	17
Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease	16
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA	16
Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics	16
Impact of GLP‐1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	16
FBXO31 sensitizes cancer stem cells‐like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma	16
Bacterial Infections in Severe Alcohol‐Associated Hepatitis: Methodological Considerations	16
Treatment patterns for hepatocellular carcinoma in patients with Child–Pugh class B and their impact on survival: A Korean nationwide registry study	16
Response to Letter to ‘Serum CRP in Durvalumab–Tremelimumab‐Treated HCC: Expanding the Inflammatory Narrative’	16
Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis	16
Identification of Distinguishing Features of Drug‐Induced Liver Injury and Liver Injury Associated With Sepsis	16
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook	16
Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis	16
Escherichia coli‐derived outer‐membrane vesicles induce immune activation and progression of cirrhosis in mice and humans	15
	15
Issue Information	15
Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study	15
Trajectories of glycaemic traits exhibit sex‐specific associations with hepatic iron and fat content: Results from the KORA‐MRI study	15
Issue Information	15
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension	15
Issue Information	15
	15
MASLD And MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint?	15
Hepatocellular carcinoma: The virus or the liver?	15
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis	15
Issue Information	15
Mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome	15
Front Cover	15
CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis	14
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma	14
Stenting of ductus venosus as a palliation for portal hypertension because of neonatal cirrhosis	14
Leflunomide‐induced liver injury: Differences in characteristics and outcomes in Indian and US registries	14
Recipient‐Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma: An ELTR Study — Author Reply	14
The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection	14
Epidemiology and surveillance of autoimmune hepatitis in Asia	14
Overcoming the challenges of eliminating viral hepatitis in low‐ and middle‐income countries	14
Sweating it out: How physical activity can combat high genetic risk for nonalcoholic fatty liver disease	14
Response Letter to: Zebrafish: An emerging and expedient model for liver studies?	14
Inhibition of IRE‐1α Alleviates Pyroptosis and Metabolic Dysfunction‐Associated Steatohepatitis by Suppressing Gasdermin D	14
A Transformer‐Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablation	14
Deficient chaperone‐mediated autophagy in macrophage aggravates inflammation of nonalcoholic steatohepatitis by targeting Nup85	14
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM	14
Response to: Letter to the Editor “Child‐Turcotte‐Pugh score as a model for organ allocation in liver transplantation, perhaps old is still gold”	14
PRO‐C3, liver fibrosis and CKD: The plot thickens	14
The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma	14
Impact of sarcopenia on postoperative outcomes after hepatectomy in older patients with intrahepatic cholangiocarcinoma: A multicentre cohort study	14
	14
Histological characterization of liver involvement in systemic mastocytosis	14
Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma	14
A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study	14
Acute alcohol‐associated hepatitis: Latest findings in non‐invasive biomarkers and treatment	14
Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China	14
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	14
Autophagy in liver regeneration: Unravelling the endothelial cell's role and therapeutic prospects	14
Inside Front Cover	14
Preoperative magnetic resonance imaging‐based prognostic model for mass‐forming intrahepatic cholangiocarcinoma	14
Novel insights into metabolic‐associated steatotic liver disease preclinical models	14
Optimizing large language models in digestive disease: strategies and challenges to improve clinical outcomes	14
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma	14
Management of alcoholic hepatitis: A clinical perspective	14
PNPLA3 variation and kidney disease	14
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	13
The immuno‐therapeutic potential of miR‐2392 in patients with hepatocellular carcinoma	13
Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non‐alcoholic fatty liver disease	13
Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US	13
Effect of common genetic variants on the risk of cirrhosis in non‐alcoholic fatty liver disease during 20 years of follow‐up	13
	13
The importance of prospective drug‐induced liver injury registries	13
Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump	13
Letter regarding ‘mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome’	13
Spatially segregated defects and IGF1‐responsiveness of hilar and peripheral biliary organoids from a model of Alagille syndrome	13
Issue Information	13
Issue Cover	13
Delta virus infection and hepatocellular carcinoma	13
Clinical characteristics and prognosis of early diagnosed Wilson's disease: A large cohort study	13
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B	13
Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030	13
Response to comments on ‘Changing landscape of alcohol‐associated liver disease in younger individuals, women and ethnic minorities’	13
Alpha‐1 Antitrypsin Inclusions Sequester GRP78 in a Bile Acid–Inducible Manner	13
Not So Quiet on the Viral Front: Low‐Level HBV Viraemia Undermines Immunotherapy in HCC	13
Mortality for Any Hepatic Cause in People With Diabetes Compared to the Non‐Diabetic Population. A 10‐Year‐Observational Study	13
Health‐related quality of life in patients aged 6–18 years with chronic hepatitis C treated with sofosbuvir/velpatasvir	13
Beneficial effects of hepatic cyclooxygenase‐2 expression against cholestatic injury after common bile duct ligation in mice	13
Exosome‐derived miR‐182‐5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK/SEMA5a/PI3K pathway	13
Can alcohol control policies reduce cirrhosis mortality? An interrupted time‐series analysis in Lithuania	13
Response Letter to: Association of thyroid function with nonalcoholic fatty liver disease in recent‐onset diabetes	13
Mortality and Cancer in Offspring of Mothers With Biopsy‐Proven MASLD During Pregnancy: A Nationwide Cohort Study	13
Excessive fatty acids activate PRMT5/MDM2/Drosha pathway to regulate miRNA biogenesis and lipid metabolism	13
Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community	13
Alcohol consumption and liver phenotype of individuals with alpha‐1 antitrypsin deficiency	13